QCIG
CRSP icon

Quad-Cities Investment Group’s CRISPR Therapeutics CRSP Stock Holding History

Quad-Cities Investment Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Buy
+4,164
New +$219K 0.08% 188

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quad-Cities Investment Group's CRSP Position: Q2 2026 in Review

Quad-Cities Investment Group opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 4,164 shares worth $227K. The stake represents 0.08% of the portfolio and ranks #188 among its holdings.

522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Quad-Cities Investment Group held 4,164 shares of CRISPR Therapeutics worth $227K as of Q2 2026.
  • CRISPR Therapeutics was a new Quad-Cities Investment Group position in Q2 2026.
  • CRISPR Therapeutics made up 0.08% of Quad-Cities Investment Group's portfolio in Q2 2026, its #188 holding.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Quad-Cities Investment Group's 13F filing for Q2 2026, filed 7 Jul 2026.